Therosteon is a new biotech fledgling emerging from the Erasmus Medical Center in Rotterdam (The Netherlands). The Company develops novel therapeutics for bone diseases including osteoporosis, osteoarthritis, and bone metastasis based on its OsteoBLAST technology platform.
Bone diseases represent an interesting market opportunity, with huge unmet medical needs. Osteoporosis in itself represents a huge market opportunity with drug sales totaling 7 billion.
Therosteon is located in incubator facilities of the Erasmus MC and collaborates closely with academic group of its scientific founder Prof. Hans van Leeuwen. |
|
T.Trimborn
Prof. Hans van Leeuwen
Marco Eijken
Bianca Boers